Treatment of coronary artery in-stent restenosis

Damianos G. Kokkinidis, Stephen W. Waldo, Ehrin J. Armstrong

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Introduction: Although drug-eluting stents (DES) have significantly reduced the incidence and prevalence of coronary in-stent restenosis (ISR), ISR still occurs in approximately 10% of patients in real-world practice. Areas covered: The development of newer generations of DES, drug-coated balloons (DCB) and increased use of intracoronary imaging have improved our treatment options for and pathophysiologic understanding of ISR. These technological advancements have also largely supplanted older modalities for treatment of ISR, such as brachytherapy, bare metal stents, conventional and cutting balloon angioplasty, and atherectomy devices. This article reviews the presentation, pathophysiology, and treatment of coronary artery ISR, with a focus on recent clinical data and emerging therapies for this difficult to treat clinical problem. Expert commentary: DCB and second-generation DES are the most effective treatment options for ISR. Most trials support a slight superiority of second-generation DES, while DCB have the advantage of not adding another metal layer. The role of bioresorbable vascular scaffolds will be determined in the near future.

Original languageEnglish (US)
Pages (from-to)191-202
Number of pages12
JournalExpert Review of Cardiovascular Therapy
Volume15
Issue number3
DOIs
StatePublished - Mar 4 2017
Externally publishedYes

Fingerprint

Stents
Coronary Vessels
Drug-Eluting Stents
Therapeutics
Metals
Pharmaceutical Preparations
Atherectomy
Balloon Angioplasty
Brachytherapy
Blood Vessels
Equipment and Supplies
Incidence

Keywords

  • Coronary artery disease
  • drug-coated balloons
  • drug-eluting stents
  • in-stent restenosis
  • percutaneous coronary intervention

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Treatment of coronary artery in-stent restenosis. / Kokkinidis, Damianos G.; Waldo, Stephen W.; Armstrong, Ehrin J.

In: Expert Review of Cardiovascular Therapy, Vol. 15, No. 3, 04.03.2017, p. 191-202.

Research output: Contribution to journalReview article

Kokkinidis, Damianos G. ; Waldo, Stephen W. ; Armstrong, Ehrin J. / Treatment of coronary artery in-stent restenosis. In: Expert Review of Cardiovascular Therapy. 2017 ; Vol. 15, No. 3. pp. 191-202.
@article{ee0254265f3249caa99ae8887c227ea4,
title = "Treatment of coronary artery in-stent restenosis",
abstract = "Introduction: Although drug-eluting stents (DES) have significantly reduced the incidence and prevalence of coronary in-stent restenosis (ISR), ISR still occurs in approximately 10{\%} of patients in real-world practice. Areas covered: The development of newer generations of DES, drug-coated balloons (DCB) and increased use of intracoronary imaging have improved our treatment options for and pathophysiologic understanding of ISR. These technological advancements have also largely supplanted older modalities for treatment of ISR, such as brachytherapy, bare metal stents, conventional and cutting balloon angioplasty, and atherectomy devices. This article reviews the presentation, pathophysiology, and treatment of coronary artery ISR, with a focus on recent clinical data and emerging therapies for this difficult to treat clinical problem. Expert commentary: DCB and second-generation DES are the most effective treatment options for ISR. Most trials support a slight superiority of second-generation DES, while DCB have the advantage of not adding another metal layer. The role of bioresorbable vascular scaffolds will be determined in the near future.",
keywords = "Coronary artery disease, drug-coated balloons, drug-eluting stents, in-stent restenosis, percutaneous coronary intervention",
author = "Kokkinidis, {Damianos G.} and Waldo, {Stephen W.} and Armstrong, {Ehrin J.}",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/14779072.2017.1284588",
language = "English (US)",
volume = "15",
pages = "191--202",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Treatment of coronary artery in-stent restenosis

AU - Kokkinidis, Damianos G.

AU - Waldo, Stephen W.

AU - Armstrong, Ehrin J.

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Introduction: Although drug-eluting stents (DES) have significantly reduced the incidence and prevalence of coronary in-stent restenosis (ISR), ISR still occurs in approximately 10% of patients in real-world practice. Areas covered: The development of newer generations of DES, drug-coated balloons (DCB) and increased use of intracoronary imaging have improved our treatment options for and pathophysiologic understanding of ISR. These technological advancements have also largely supplanted older modalities for treatment of ISR, such as brachytherapy, bare metal stents, conventional and cutting balloon angioplasty, and atherectomy devices. This article reviews the presentation, pathophysiology, and treatment of coronary artery ISR, with a focus on recent clinical data and emerging therapies for this difficult to treat clinical problem. Expert commentary: DCB and second-generation DES are the most effective treatment options for ISR. Most trials support a slight superiority of second-generation DES, while DCB have the advantage of not adding another metal layer. The role of bioresorbable vascular scaffolds will be determined in the near future.

AB - Introduction: Although drug-eluting stents (DES) have significantly reduced the incidence and prevalence of coronary in-stent restenosis (ISR), ISR still occurs in approximately 10% of patients in real-world practice. Areas covered: The development of newer generations of DES, drug-coated balloons (DCB) and increased use of intracoronary imaging have improved our treatment options for and pathophysiologic understanding of ISR. These technological advancements have also largely supplanted older modalities for treatment of ISR, such as brachytherapy, bare metal stents, conventional and cutting balloon angioplasty, and atherectomy devices. This article reviews the presentation, pathophysiology, and treatment of coronary artery ISR, with a focus on recent clinical data and emerging therapies for this difficult to treat clinical problem. Expert commentary: DCB and second-generation DES are the most effective treatment options for ISR. Most trials support a slight superiority of second-generation DES, while DCB have the advantage of not adding another metal layer. The role of bioresorbable vascular scaffolds will be determined in the near future.

KW - Coronary artery disease

KW - drug-coated balloons

KW - drug-eluting stents

KW - in-stent restenosis

KW - percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=85014582034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014582034&partnerID=8YFLogxK

U2 - 10.1080/14779072.2017.1284588

DO - 10.1080/14779072.2017.1284588

M3 - Review article

VL - 15

SP - 191

EP - 202

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 3

ER -